Related Experiment Video
Updated: Sep 18, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized
Sajjad Biglari1,2, Harald Mischak1, Joachim Beige3,4
1Mosaiques Diagnostics GmbH, 30659 Hannover, Germany.
Insights
This review explores recent advances in chronic kidney disease (CKD) pharmacotherapy, focusing on drug combinations and personalized treatments using biomarkers for better patient outcomes.
Area of Science:
- Nephrology
- Pharmacology
- Biomarkers
Background:
- Chronic kidney disease (CKD) is a significant global health issue with rising incidence and costs.
- Current healthcare systems face challenges in managing the growing CKD patient population.
Purpose of the Study:
- To provide an in-depth assessment of advances in CKD pharmacotherapy from 2020-2025.
- To emphasize the role of drug combinations and biomarker-guided therapy in personalized CKD management.
Main Methods:
- Systematic literature search for studies published between 2020 and 2025.
- Narrative review synthesizing findings on CKD pharmacotherapy, drug combinations, and predictive biomarkers.
Main Results:
- Drug combinations offer potential for improved CKD outcomes but carry risks of adverse effects and costs.
- Biomarker-based approaches enable personalized CKD treatment tailored to individual molecular profiles.
- Current methods for guiding CKD therapy based on treatment response markers are presented.
Conclusions:
- Personalized medicine, utilizing biomarkers, holds promise for optimizing CKD treatment strategies.
- Combining pharmacotherapies and biomarker-guided approaches may lead to more effective CKD management.
- Further research into tailored therapies can improve patient outcomes and reduce healthcare burdens.
Abstract:
Chronic kidney disease (CKD) is a global health burden that affects close to one billion individuals. As many healthcare systems struggle to accommodate existing patients, CKD incidence and related costs are projected to continue rising. Based on a systematic search, this narrative review offers an in-depth assessment of advances in CKD pharmacotherapy published between 2020 and 2025, with a specific emphasis on drug combinations. Various treatment approaches for CKD exist, many of them targeting different mechanisms. Therefore, combining multiple medications could provide patients with better outcomes, though this comes with the risk of increased adverse effects and unnecessary costs. Alternatively, using biomarkers presents an opportunity to ascertain the most appropriate treatments specifically tailored to an individual's molecular profile, thus personalizing CKD management. The second part of this review presents the current state-of-the-art methods to guide CKD therapy based on markers predicting treatment response. Collectively, this review presents possible pathways toward more effective CKD treatment.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations

